Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;2010(21):3631-3636.
doi: 10.1055/s-0030-1258245.

Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators

Affiliations

Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators

Raymond J Bergeron et al. Synthesis (Stuttg). 2010.

Abstract

Iron chelators have been shown to control the growth of cancer cells in culture by sequestering exogenous iron in the media. Thus, the ligands prevent cellular access to the metal. However, because transferrin provides iron to tumor cells in animals, chelators have not been effective antitumor agents. Polyamine chelator conjugates in which the polyamine vectored ligands into cells were far more active than the free chelators themselves. However, the free ligands were not released from the vector once in the cell. The current study focuses on the synthesis and preliminary evaluation of a polyamine chelator conjugate capable of releasing the free ligand intracellularly via a nonspecific esterase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Polyamine analogue DENSPM (1), chelators 2 and 6, and polyamine analogue chelator conjugates 3,4,5,7
Scheme 1
Scheme 1
Reagents and conditions: (a) mesitylenesulfonyl chloride, aq 1 N NaOH, CH2Cl2, 67%; (b) 4-(tert-butoxycarbonyl)benzyl bromide, 60% NaH, DMF, 70 °C, 70%; (c) 30% HBr in AcOH, PhOH, CH2Cl2, 84%; (d) BOC2O, aq THF, Et3N, 85%; (e) EDAC, DMAP, CH2Cl2, 55%; (f) TFA, CH2Cl2, ion exchange, aq 1 N HCl, quantitative.

Similar articles

Cited by

References

    1. Bergeron RJ. Trends Biochem. Sci. 1986;11:133–136.
    2. Bergeron RJ, Braylan R, Goldey S, Ingeno MJ. Biochem. Biophys. Res. Commun. 1986;136:273–280. - PubMed
    3. Hershko C. Bailliere’s Clin. Haematol. 1994;7:965–1000. - PubMed
    4. Chenoufi N, Drenou B, Loreal O, Pigeon C, Brissot P, Lescoat G. Biochem. Pharmacol. 1998;56:431–437. - PubMed
    1. Bergeron RJ, Ingeno MJ. Cancer Res. 1987;47:6010–6016. - PubMed
    2. Taetle R, Honeysett JM, Bergeron RJ. J. Natl. Cancer Inst. 1989;81:1229–1235. - PubMed
    3. Nyholm S, Mann GJ, Johannson AG, Bergeron RJ, Graslund A, Thelander L. J. Biol. Chem. 1993;268:26200–26205. - PubMed
    1. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC. Blood. 1988;72:1497–1503. - PubMed
    1. Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D. Cancer Res. 1998;58:473–478. - PubMed
    1. Marton LJ, Pegg AE. Annu. Rev. Pharm. Toxicol. 1995;35:55–91. - PubMed
    2. Thomas T, Balabhadrapathruni S, Gallo MA, Thomas TJ. Oncol. Res. 2002;13:123–135. - PubMed
    3. Wallace HM, Fraser AV. Biochem. Soc. Trans. 2003;31:393–396. - PubMed